DOUGLAS FISHER, M.D. - Corporate Board Profile

Precipio, Inc.

Filing Date	Source Excerpt
2018-05-29	Douglas Fisher, M.D. 41 Director, Member of the Compensation Committee and Audit Committee 2017 2020 Director Summary Compensation Table Douglas Fisher 42,000 11,200 53,200
2018-11-27	Douglas Fisher, M.D. Consists solely of shares of Common Stock issuable upon the exercise of stock options that are exercisable or will become exercisable within 60 days after November 7, 2018.
2019-04-29	Douglas Fisher 44,687 2,068 5,170 2/16/2018 10.65 70,582 115,269
2020-04-29	Douglas Fisher, M.D. Interim Chairman, Chair of the Compensation Committee and Member of the Audit Committee. The current members of the Audit Committee are directors Ms. LaPorte, the Chairperson of the Audit Committee, Dr. Fisher and Mr. Rimer, all of whom have been determined by the Board to be independent under the Nasdaq listing standards and rules adopted by the SEC applicable to audit committee members. The Compensation Committee currently consists of directors Dr. Fisher and Mr. Rimer. Each of the Compensation Committee members has been determined by the Board to be independent under Nasdaq listing standards applicable to compensation committee members. The Compensation Committee met six times in 2019 during each of the quarterly meetings and two additional telephonic meetings. The Compensation Committee did not take any actions by written consent. Director Summary Compensation Table: Douglas Fisher Fees Earned or Paid in Cash $26,500, Option Awards $10,200, Total $36,700.
2021-04-29	Douglas Fisher, M.D. Mr. Fisher, age 45, was appointed as director of the Company in September 2017. Dr. Fisher is currently an Executive in Residence at InterWest Partners LLC, a venture capital firm, where he has worked since March 2009. Dr. Fisher also works and serves as the Chief Business Officer at Sera Prognostics, Inc. since January 2015. Prior to joining InterWest, Dr. Fisher served as Vice President of New Leaf Venture Partners LLC, a private equity and venture capital firm, from January 2006 to March 2009. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group, Inc., a global management consulting firm, from November 2003 to February 2006. He currently serves on the board of Obalon Therapeutics, Inc., Gynesonics, Inc. Lycera Pharmaceuticals Corp and Indi Molecular, Inc., and previously served on the board of QuatRx Pharmaceuticals Company, Cardiac Dimensions, PMV Pharmaceuticals, Inc. and Sera Prognostics, Inc. Dr. Fisher holds an A.B. and a B.S. from Stanford University, an M.D. from the University of Pennsylvania School of Medicine and an MBA from The Wharton School of Business at the University of Pennsylvania. Dr. Fisher’s diverse background as both a physician, and an investor in biotech markets, is extremely beneficial to the Board in planning the Company’s strategic growth and how to approach and manage the financial markets.
2022-04-28	Douglas Fisher, M.D. Dr. Fisher, age 46, was appointed as director of the Company in September 2017. Dr. Fisher is currently a Partner at Revelation Partners, a private equity firm, where he has worked since 2020 as well as a Venture Partner at InterWest Partners LLC, a venture capital firm, where he has worked since March 2009. Dr. Fisher also served as the Chief Business Officer for Sera Prognostics from 2015-2022. Prior to joining InterWest, Dr. Fisher served as Vice President of New Leaf Venture Partners LLC, a private equity firm, from January 2006 to March 2009. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group, Inc., a global management consulting firm, from November 2003 to February 2006. He currently serves on the board of Aspen Neurosciences, Indi Molecular, Inc., and WeavR Health and previously served on the board of Obalon Therapeutics, Inc., Gynesonics, Inc., Lycera Pharmaceuticals Corp, QuatRx Pharmaceuticals Company, Cardiac Dimensions, PMV Pharmaceuticals, Inc. and Sera Prognostics, Inc. Dr. Fisher holds an A.B. and a B.S. from Stanford University, an M.D. from the University of Pennsylvania School of Medicine and an MBA from The Wharton School of Business at the University of Pennsylvania. Dr. Fisher’s diverse background as both a physician, and an investor in biotech markets, is extremely beneficial to the Board in planning the Company’s strategic growth and how to approach and manage the financial markets.
2023-04-25	Douglas Fisher, M.D. Mr. Fisher, age 47, was appointed as director of the Company in September 2017. ... The Compensation Committee currently consists of directors Dr. Fisher and Mr. Andrews. ... The Audit Committee current members are Ms. LaPorte, Dr. Fisher and Mr. Sandberg. ... Director Summary Compensation Table The following table provides information regarding our compensation for non-employee directors during the fiscal year ended December 31, 2022. ... Douglas Fisher Fees Earned or Paid in Cash ($) 52,500 Option Awards ($) 59,200 Total ($) 111,700.